Search research articles
Contact Us
Filters
Showing results (1-10 of 65) with videos related to
Page
of 7
Sort By:
The New England Journal of Medicine
|
June 2, 2016
Therapy for Tuberculous Meningitis
Reinout van Crevel, Rovina Ruslami, Rob Aarnoutse
The New England Journal of Medicine
|
February 5, 2015
Shorter moxifloxacin-based regimens for drug-sensitive tuberculosis
Jan-Willem Alffenaar, Tawanda Gumbo, Rob Aarnoutse
ERJ Open Research
|
December 24, 2025
Survey on therapeutic drug monitoring practices for nontuberculous mycobacterial infections: an NTMnet/ESGMYC collaborative study
Victor Næstholt Dahl, Nicole Maranchick, Jakko van Ingen, et al.
Antimicrobial Agents and Chemotherapy
|
December 24, 2013
Reply to "strategy to limit sampling of antituberculosis drugs instead of determining concentrations at two hours postingestion in relation to treatment response"
Rob Aarnoutse, Carolien Ruesen, Erlina Burhan, et al.
Therapeutic Drug Monitoring
|
March 9, 2011
The International Interlaboratory Quality Control Program for Measurement of Antiretroviral Drugs in Plasma: a global proficiency testing program
David Burger, Marga Teulen, Jaco Eerland, et al.
Therapeutic Drug Monitoring
|
May 14, 2014
Poor performance of laboratories assaying newly developed antiretroviral agents: results for darunavir, etravirine, and raltegravir from the international quality control program for therapeutic drug monitoring of antiretroviral drugs in human plasma/serum
David Burger, Stefanie Krens, Karen Robijns, et al.
British Journal of Clinical Pharmacology
|
March 30, 2019
Pharmacokinetics, safety and tolerability of the novel β-hCG derived immunomodulatory compound, EA-230
Roger van Groenendael, Rob Aarnoutse, Matthijs Kox, et al.
Pulmonary Pharmacology & Therapeutics
|
December 20, 2011
Therapeutic drug monitoring in the treatment of tuberculosis patients
Cecile Magis-Escurra, Jossy van den Boogaard, Dirk Ijdema, et al.
Antimicrobial Agents and Chemotherapy
|
October 25, 2023
The role of rifampicin within the treatment of <i>Mycobacterium avium</i> pulmonary disease
Jodie A Schildkraut, Jelmer Raaijmakers, Rob Aarnoutse, et al.
The Journal of Antimicrobial Chemotherapy
|
April 3, 2024
Influence of ultrafiltration conditions on the measurement of unbound drug concentrations: flucloxacillin as an example
Nynke G L Jager, Eleonora Van Ewijk-Beneken Kolmer, Rob Aarnoutse, et al.
Page
of 7
Search research articles
Search
Showing results (1-10 of 65) with videos related to
Sort By:
Page
of 7
The New England Journal of Medicine
|
June 2, 2016
Therapy for Tuberculous Meningitis
Reinout van Crevel, Rovina Ruslami, Rob Aarnoutse
The New England Journal of Medicine
|
February 5, 2015
Shorter moxifloxacin-based regimens for drug-sensitive tuberculosis
Jan-Willem Alffenaar, Tawanda Gumbo, Rob Aarnoutse
ERJ Open Research
|
December 24, 2025
Survey on therapeutic drug monitoring practices for nontuberculous mycobacterial infections: an NTMnet/ESGMYC collaborative study
Victor Næstholt Dahl, Nicole Maranchick, Jakko van Ingen, et al.
Antimicrobial Agents and Chemotherapy
|
December 24, 2013
Reply to "strategy to limit sampling of antituberculosis drugs instead of determining concentrations at two hours postingestion in relation to treatment response"
Rob Aarnoutse, Carolien Ruesen, Erlina Burhan, et al.
Therapeutic Drug Monitoring
|
March 9, 2011
The International Interlaboratory Quality Control Program for Measurement of Antiretroviral Drugs in Plasma: a global proficiency testing program
David Burger, Marga Teulen, Jaco Eerland, et al.
Therapeutic Drug Monitoring
|
May 14, 2014
Poor performance of laboratories assaying newly developed antiretroviral agents: results for darunavir, etravirine, and raltegravir from the international quality control program for therapeutic drug monitoring of antiretroviral drugs in human plasma/serum
David Burger, Stefanie Krens, Karen Robijns, et al.
British Journal of Clinical Pharmacology
|
March 30, 2019
Pharmacokinetics, safety and tolerability of the novel β-hCG derived immunomodulatory compound, EA-230
Roger van Groenendael, Rob Aarnoutse, Matthijs Kox, et al.
Pulmonary Pharmacology & Therapeutics
|
December 20, 2011
Therapeutic drug monitoring in the treatment of tuberculosis patients
Cecile Magis-Escurra, Jossy van den Boogaard, Dirk Ijdema, et al.
Antimicrobial Agents and Chemotherapy
|
October 25, 2023
The role of rifampicin within the treatment of <i>Mycobacterium avium</i> pulmonary disease
Jodie A Schildkraut, Jelmer Raaijmakers, Rob Aarnoutse, et al.
The Journal of Antimicrobial Chemotherapy
|
April 3, 2024
Influence of ultrafiltration conditions on the measurement of unbound drug concentrations: flucloxacillin as an example
Nynke G L Jager, Eleonora Van Ewijk-Beneken Kolmer, Rob Aarnoutse, et al.
Page
of 7